Seguir
Andrea López-Martínez
Andrea López-Martínez
PhD candidate, Biobizkaia Health Research Institute
Dirección de correo verificada de osakidetza.eus - Página principal
Título
Citado por
Citado por
Año
An overview of alternative splicing defects implicated in myotonic dystrophy type I
A López-Martínez, P Soblechero-Martín, L de-la-Puente-Ovejero, ...
Genes 11 (9), 1109, 2020
902020
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
P Soblechero‐Martín, A López‐Martínez, L de la Puente‐Ovejero, ...
Neuropathology and Applied Neurobiology 47 (6), 711-723, 2021
332021
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
P Soblechero-Martin, E Albiasu-Arteta, A Anton-Martinez, ...
Scientific Reports, 18188, 2021
142021
Evaluation of exon skipping and dystrophin restoration in in vitro models of duchenne muscular dystrophy
A López-Martínez, P Soblechero-Martín, V Arechavala-Gomeza
Antisense RNA Design, Delivery, and Analysis, 217-233, 2022
42022
Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model
J Poyatos-Garcia, P Soblechero-Martin, A Liquori, A Lopez-Martinez, ...
bioRxiv, 2023.09. 13.557649, 2023
2023
VP. 88 Characterisation of cell culture models of myotonic dystrophy type I by In-Cell Western technology and digital droplet PCR
A López-Martínez, P Soblechero-Martín, C Catalli, A Jauregui-Barrutia, ...
Neuromuscular Disorders 32, S132-S133, 2022
2022
Optimisation of a Cell-Based Strategy for Rapid Evaluation of Compounds in Myotonic Dystrophy Type I
A López-Martínez, P Soblechero-Martín, C Catalli, A Jauregi-Barrutia, ...
17th International Congress on Neuromuscular Diseases 9 (s1), S139, 2022
2022
Búsqueda de compuestos moduladores de STAU1 mediante herramientas computacionales para su aplicación en la distrofia miotónica tipo I
A López Martínez
Universitat Oberta de Catalunya (UOC), 2022
2022
DMD-BIOMARKERS: EP. 161 A novel cell-based screening assay for the identification of utrophin-upregulating compounds
P Soblechero-Martín, A López-Martínez, V Arechavala-Gomeza
Neuromuscular Disorders 31, S98, 2021
2021
A CRISPR/Cas9 edition protocol for human myoblasts to generate disease models
P Soblechero-Martin, E Albiasu-Arteta, A Anton-Martinez, ...
HUMAN GENE THERAPY 30 (11), A189-A189, 2019
2019
P. 291Overcoming barriers to establish a CRISPR/Cas9 edition protocol for human myoblasts
P Soblechero-Martin, E Albiasu-Arteta, J Poyatos-García, ...
Neuromuscular Disorders 29, S152, 2019
2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–11